{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T15:37:14Z","timestamp":1785253034207,"version":"3.55.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40120-026-00931-1","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T14:37:53Z","timestamp":1775831873000},"page":"925-949","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Treatment Effects on Chronic Active Lesions in Multiple Sclerosis: Current Evidence and Future Perspectives"],"prefix":"10.1007","volume":"15","author":[{"given":"Paolo","family":"Preziosa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Guido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Filippi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2358-4320","authenticated-orcid":false,"given":"Maria A.","family":"Rocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"issue":"1","key":"931_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-018-0041-4","volume":"4","author":"M Filippi","year":"2018","unstructured":"Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S, et al. Multiple sclerosis. Nat Rev Dis Primers. 2018;4(1):43. https:\/\/doi.org\/10.1038\/s41572-018-0041-4.","journal-title":"Nat Rev Dis Primers"},{"issue":"9","key":"931_CR2","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1093\/brain\/awae013","volume":"147","author":"F Bagnato","year":"2024","unstructured":"Bagnato F, Sati P, Hemond CC, Elliott C, Gauthier SA, Harrison DM, et al. Imaging chronic active lesions in multiple sclerosis: a consensus statement. Brain. 2024;147(9):2913\u201333. https:\/\/doi.org\/10.1093\/brain\/awae013.","journal-title":"Brain"},{"issue":"19","key":"931_CR3","doi-asserted-by":"publisher","first-page":"3231","DOI":"10.1016\/j.neuron.2024.05.025","volume":"112","author":"T Garton","year":"2024","unstructured":"Garton T, Gadani SP, Gill AJ, Calabresi PA. Neurodegeneration and demyelination in multiple sclerosis. Neuron. 2024;112(19):3231\u201351. https:\/\/doi.org\/10.1016\/j.neuron.2024.05.025.","journal-title":"Neuron"},{"issue":"3","key":"931_CR4","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.243718","volume":"316","author":"M Tranfa","year":"2025","unstructured":"Tranfa M, Cantoni V, Green R, Carignani G, Capasso S, Brescia Morra V, et al. Prevalence and incidence of paramagnetic rim lesions in multiple sclerosis: a systematic review and meta-analysis. Radiology. 2025;316(3):e243718. https:\/\/doi.org\/10.1148\/radiol.243718.","journal-title":"Radiology"},{"issue":"1","key":"931_CR5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00401-016-1653-y","volume":"133","author":"T Kuhlmann","year":"2017","unstructured":"Kuhlmann T, Ludwin S, Prat A, Antel J, Bruck W, Lassmann H. An updated histological classification system for multiple sclerosis lesions. Acta Neuropathol. 2017;133(1):13\u201324. https:\/\/doi.org\/10.1007\/s00401-016-1653-y.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"931_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00401-016-1636-z","volume":"133","author":"A Dal-Bianco","year":"2017","unstructured":"Dal-Bianco A, Grabner G, Kronnerwetter C, Weber M, Hoftberger R, Berger T, et al. Slow expansion of multiple sclerosis iron rim lesions: pathology and 7 T magnetic resonance imaging. Acta Neuropathol. 2017;133(1):25\u201342. https:\/\/doi.org\/10.1007\/s00401-016-1636-z.","journal-title":"Acta Neuropathol"},{"issue":"3","key":"931_CR7","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1093\/brain\/awaa436","volume":"144","author":"A Dal-Bianco","year":"2021","unstructured":"Dal-Bianco A, Grabner G, Kronnerwetter C, Weber M, Kornek B, Kasprian G, et al. Long-term evolution of multiple sclerosis iron rim lesions in 7 T MRI. Brain. 2021;144(3):833\u201347. https:\/\/doi.org\/10.1093\/brain\/awaa436.","journal-title":"Brain"},{"issue":"1","key":"931_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-025-02122-9","volume":"13","author":"L Najm","year":"2025","unstructured":"Najm L, Chomyk A, Cyncynatus K, Davalos D, Mahajan KR, Trapp BD. Demyelinated lesion associated compartmental inflammation in progressive multiple sclerosis brains. Acta Neuropathol Commun. 2025;13(1):204. https:\/\/doi.org\/10.1186\/s40478-025-02122-9.","journal-title":"Acta Neuropathol Commun"},{"issue":"12","key":"931_CR9","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1001\/jamaneurol.2019.2399","volume":"76","author":"M Absinta","year":"2019","unstructured":"Absinta M, Sati P, Masuzzo F, Nair G, Sethi V, Kolb H, et al. Association of chronic active multiple sclerosis lesions with disability in vivo. JAMA Neurol. 2019;76(12):1474\u201383. https:\/\/doi.org\/10.1001\/jamaneurol.2019.2399.","journal-title":"JAMA Neurol"},{"issue":"10","key":"931_CR10","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000210004","volume":"103","author":"JA Reeves","year":"2024","unstructured":"Reeves JA, Bartnik A, Jakimovski D, Mohebbi M, Bergsland N, Salman F, et al. Associations between paramagnetic rim lesion evolution and clinical and radiologic disease progression in persons with multiple sclerosis. Neurology. 2024;103(10):e210004. https:\/\/doi.org\/10.1212\/WNL.0000000000210004.","journal-title":"Neurology"},{"key":"931_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2025.106804","volume":"104","author":"LA Zarco","year":"2025","unstructured":"Zarco LA, Cardenas-Cruz AF, Munoz O, Canellas AR. Paramagnetic iron rim lesions as a prognostic factor for disability progression in multiple sclerosis: a systematic review of the literature. Mult Scler Relat Disord. 2025;104:106804. https:\/\/doi.org\/10.1016\/j.msard.2025.106804.","journal-title":"Mult Scler Relat Disord"},{"issue":"7","key":"931_CR12","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1172\/JCI86198","volume":"126","author":"M Absinta","year":"2016","unstructured":"Absinta M, Sati P, Schindler M, Leibovitch EC, Ohayon J, Wu T, et al. Persistent 7-tesla phase rim predicts poor outcome in new multiple sclerosis patient lesions. J Clin Invest. 2016;126(7):2597\u2013609. https:\/\/doi.org\/10.1172\/JCI86198.","journal-title":"J Clin Invest"},{"issue":"6","key":"931_CR13","doi-asserted-by":"publisher","first-page":"987","DOI":"10.3174\/ajnr.A6071","volume":"40","author":"S Zhang","year":"2019","unstructured":"Zhang S, Nguyen TD, Hurtado Rua SM, Kaunzner UW, Pandya S, Kovanlikaya I, et al. Quantitative susceptibility mapping of time-dependent susceptibility changes in multiple sclerosis lesions. AJNR Am J Neuroradiol. 2019;40(6):987\u201393. https:\/\/doi.org\/10.3174\/ajnr.A6071.","journal-title":"AJNR Am J Neuroradiol"},{"issue":"2","key":"931_CR14","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1002\/acn3.52253","volume":"12","author":"JA Reeves","year":"2025","unstructured":"Reeves JA, Bartnik A, Mohebbi M, Ramanathan M, Bergsland N, Jakimovski D, et al. Determinants of long-term paramagnetic rim lesion evolution in people with multiple sclerosis. Ann Clin Transl Neurol. 2025;12(2):267\u201379. https:\/\/doi.org\/10.1002\/acn3.52253.","journal-title":"Ann Clin Transl Neurol"},{"issue":"14","key":"931_CR15","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1177\/1352458518814117","volume":"25","author":"C Elliott","year":"2019","unstructured":"Elliott C, Wolinsky JS, Hauser SL, Kappos L, Barkhof F, Bernasconi C, et al. Slowly expanding\/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions. Mult Scler. 2019;25(14):1915\u201325. https:\/\/doi.org\/10.1177\/1352458518814117.","journal-title":"Mult Scler"},{"issue":"17","key":"931_CR16","doi-asserted-by":"publisher","first-page":"e1783","DOI":"10.1212\/WNL.0000000000200144","volume":"98","author":"A Calvi","year":"2022","unstructured":"Calvi A, Carrasco FP, Tur C, Chard DT, Stutters J, De Angelis F, et al. Association of slowly expanding lesions on MRI with disability in people with secondary progressive multiple sclerosis. Neurology. 2022;98(17):e1783\u201393. https:\/\/doi.org\/10.1212\/WNL.0000000000200144.","journal-title":"Neurology"},{"issue":"4","key":"931_CR17","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1177\/13524585251316519","volume":"31","author":"I Vavasour","year":"2025","unstructured":"Vavasour I, Elliott C, Arnold DL, Gaetano L, Clayton D, Magon S, et al. Presence of slowly expanding lesions in multiple sclerosis predicts progressive demyelination within lesions and normal-appearing tissue over time. Mult Scler. 2025;31(4):418\u201332. https:\/\/doi.org\/10.1177\/13524585251316519.","journal-title":"Mult Scler"},{"key":"931_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2025-335884","author":"A Calvi","year":"2025","unstructured":"Calvi A, Vivo Pascual F, Solana E, Lopez-Soley E, Kanber B, Alba-Arbalat S, et al. Diffusivity anisotropy signature of the slowly expanding lesions predicts progression independent of relapse activity in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2025. https:\/\/doi.org\/10.1136\/jnnp-2025-335884.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9","key":"931_CR19","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1093\/brain\/awz212","volume":"142","author":"C Elliott","year":"2019","unstructured":"Elliott C, Belachew S, Wolinsky JS, Hauser SL, Kappos L, Barkhof F, et al. Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis. Brain. 2019;142(9):2787\u201399. https:\/\/doi.org\/10.1093\/brain\/awz212.","journal-title":"Brain"},{"issue":"10","key":"931_CR20","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1177\/1352458520969105","volume":"27","author":"P Preziosa","year":"2021","unstructured":"Preziosa P, Pagani E, Moiola L, Rodegher M, Filippi M, Rocca MA. Occurrence and microstructural features of slowly expanding lesions on fingolimod or natalizumab treatment in multiple sclerosis. Mult Scler. 2021;27(10):1520\u201332. https:\/\/doi.org\/10.1177\/1352458520969105.","journal-title":"Mult Scler"},{"issue":"2","key":"931_CR21","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/ana.26657","volume":"94","author":"M Hamzaoui","year":"2023","unstructured":"Hamzaoui M, Garcia J, Boffa G, Lazzarotto A, Absinta M, Ricigliano VAG, et al. Positron emission tomography with [(18) F]-DPA-714 unveils a smoldering component in most multiple sclerosis lesions which drives disease progression. Ann Neurol. 2023;94(2):366\u201383. https:\/\/doi.org\/10.1002\/ana.26657.","journal-title":"Ann Neurol"},{"issue":"8","key":"931_CR22","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1111\/ene.15834","volume":"30","author":"J Lehto","year":"2023","unstructured":"Lehto J, Nylund M, Matilainen M, Sucksdorff M, Vuorimaa A, Rajander J, et al. Longitudinal stability of progression-related microglial activity during teriflunomide treatment in patients with multiple sclerosis. Eur J Neurol. 2023;30(8):2365\u201375. https:\/\/doi.org\/10.1111\/ene.15834.","journal-title":"Eur J Neurol"},{"issue":"1","key":"931_CR23","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcab301","volume":"4","author":"M Nylund","year":"2022","unstructured":"Nylund M, Sucksdorff M, Matilainen M, Polvinen E, Tuisku J, Airas L. Phenotyping of multiple sclerosis lesions according to innate immune cell activation using 18 kDa translocator protein-PET. Brain Commun. 2022;4(1):fcab301. https:\/\/doi.org\/10.1093\/braincomms\/fcab301.","journal-title":"Brain Commun"},{"issue":"6","key":"931_CR24","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1038\/s41591-025-03625-7","volume":"31","author":"L Klotz","year":"2025","unstructured":"Klotz L, Smolders J, Lehto J, Matilainen M, Lutje L, Buchholz L, et al. Broad rim lesions are a new pathological and imaging biomarker for rapid disease progression in multiple sclerosis. Nat Med. 2025;31(6):2016\u201326. https:\/\/doi.org\/10.1038\/s41591-025-03625-7.","journal-title":"Nat Med"},{"issue":"14","key":"931_CR25","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1177\/13524585241284157","volume":"30","author":"CA Treaba","year":"2024","unstructured":"Treaba CA, Herranz E, Barletta VT, Mehndiratta A, Sloane JA, Granberg T, et al. Phenotyping in vivo chronic inflammation in multiple sclerosis by combined (11)C-PBR28 MR-PET and 7T susceptibility-weighted imaging. Mult Scler. 2024;30(14):1755\u201364. https:\/\/doi.org\/10.1177\/13524585241284157.","journal-title":"Mult Scler"},{"key":"931_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2025.106546","volume":"100","author":"G Guido","year":"2025","unstructured":"Guido G, Preziosa P, Filippi M, Rocca MA. TSPO PET in multiple sclerosis: emerging insights into pathophysiology, prognosis, and treatment monitoring. Mult Scler Relat Disord. 2025;100:106546. https:\/\/doi.org\/10.1016\/j.msard.2025.106546.","journal-title":"Mult Scler Relat Disord"},{"issue":"5","key":"931_CR27","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1002\/ana.24791","volume":"80","author":"E Herranz","year":"2016","unstructured":"Herranz E, Gianni C, Louapre C, Treaba CA, Govindarajan ST, Ouellette R, et al. Neuroinflammatory component of gray matter pathology in multiple sclerosis. Ann Neurol. 2016;80(5):776\u201390. https:\/\/doi.org\/10.1002\/ana.24791.","journal-title":"Ann Neurol"},{"issue":"1","key":"931_CR28","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1093\/brain\/awy296","volume":"142","author":"UW Kaunzner","year":"2019","unstructured":"Kaunzner UW, Kang Y, Zhang S, Morris E, Yao Y, Pandya S, et al. Quantitative susceptibility mapping identifies inflammation in a subset of chronic multiple sclerosis lesions. Brain. 2019;142(1):133\u201345. https:\/\/doi.org\/10.1093\/brain\/awy296.","journal-title":"Brain"},{"issue":"4","key":"931_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurad.2023.10.010","volume":"51","author":"E Vanheule","year":"2024","unstructured":"Vanheule E, Cambron M, Dobai A, Casselman JW. Rim lesions in MS at 3T: clinical correlation and possible radiological alternatives for daily practice at lower field strength. J Neuroradiol. 2024;51(4):101165. https:\/\/doi.org\/10.1016\/j.neurad.2023.10.010.","journal-title":"J Neuroradiol"},{"issue":"14","key":"931_CR30","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1177\/13524585221106338","volume":"28","author":"P Eisele","year":"2022","unstructured":"Eisele P, Wittayer M, Weber CE, Platten M, Schirmer L, Gass A. Impact of disease-modifying therapies on evolving tissue damage in iron rim multiple sclerosis lesions. Mult Scler. 2022;28(14):2294\u20138. https:\/\/doi.org\/10.1177\/13524585221106338.","journal-title":"Mult Scler"},{"key":"931_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1343531","volume":"15","author":"H Tan","year":"2024","unstructured":"Tan H, Li X, Li Y, He F, ZhangBao J, Zhou L, et al. Real-world experience of teriflunomide in relapsing multiple sclerosis: paramagnetic rim lesions may play a role. Front Immunol. 2024;15:1343531. https:\/\/doi.org\/10.3389\/fimmu.2024.1343531.","journal-title":"Front Immunol"},{"key":"931_CR32","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001138","author":"N Zinger","year":"2022","unstructured":"Zinger N, Ponath G, Sweeney E, Nguyen TD, Lo CH, Diaz I, et al. Dimethyl fumarate reduces inflammation in chronic active multiple sclerosis lesions. Neurol Neuroimmunol Neuroinflamm. 2022. https:\/\/doi.org\/10.1212\/NXI.0000000000001138.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"931_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2025.106339","volume":"96","author":"M Marrodan","year":"2025","unstructured":"Marrodan M, Yanez P, Calandri IL, Piedrabuena MA, Zarate MA, Ysrraelit MC, et al. Impact of oral cladribine on paramagnetic rim lesions of multiple sclerosis patients. Mult Scler Relat Disord. 2025;96:106339. https:\/\/doi.org\/10.1016\/j.msard.2025.106339.","journal-title":"Mult Scler Relat Disord"},{"key":"931_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104701","volume":"94","author":"P Maggi","year":"2023","unstructured":"Maggi P, Bulcke CV, Pedrini E, Bugli C, Sellimi A, Wynen M, et al. B cell depletion therapy does not resolve chronic active multiple sclerosis lesions. EBioMedicine. 2023;94:104701. https:\/\/doi.org\/10.1016\/j.ebiom.2023.104701.","journal-title":"EBioMedicine"},{"issue":"8","key":"931_CR35","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-025-13221-x","volume":"272","author":"A Cagol","year":"2025","unstructured":"Cagol A, Schaedelin S, Ocampo-Pineda M, Benkert P, Melie-Garcia L, Luchetti L, et al. Comparative effectiveness of teriflunomide and ocrelizumab on smoldering activity in multiple sclerosis: an observational study in the Swiss Multiple Sclerosis Cohort. J Neurol. 2025;272(8):491. https:\/\/doi.org\/10.1007\/s00415-025-13221-x.","journal-title":"J Neurol"},{"issue":"1","key":"931_CR36","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200506","volume":"13","author":"R Nistri","year":"2026","unstructured":"Nistri R, De Meo E, Kim NN, Pozzilli V, Goebl P, Sa M, et al. Paramagnetic rim lesions in pediatric multiple sclerosis and their association with brain tissue atrophy. Neurol Neuroimmunol Neuroinflamm. 2026;13(1):e200506. https:\/\/doi.org\/10.1212\/NXI.0000000000200506.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"931_CR37","doi-asserted-by":"publisher","unstructured":"Markowitz KH, Safi NV, Dimov A, Kaunzner UW, Luu H, Sisman M, et al. Quantifying the impact of ocrelizumab on paramagnetic rim lesions in multiple sclerosis. medRxiv. 2025:2025.05.20.25328011. https:\/\/doi.org\/10.1101\/2025.05.20.25328011.","DOI":"10.1101\/2025.05.20.25328011"},{"issue":"4","key":"931_CR38","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1001\/jamaneurol.2022.5332","volume":"80","author":"S Dybowski","year":"2023","unstructured":"Dybowski S, Torke S, Weber MS. Targeting B cells and microglia in multiple sclerosis with Bruton tyrosine kinase inhibitors: a review. JAMA Neurol. 2023;80(4):404\u201314. https:\/\/doi.org\/10.1001\/jamaneurol.2022.5332.","journal-title":"JAMA Neurol"},{"issue":"5","key":"931_CR39","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41582-023-00800-7","volume":"19","author":"J Kramer","year":"2023","unstructured":"Kramer J, Bar-Or A, Turner TJ, Wiendl H. Bruton tyrosine kinase inhibitors for multiple sclerosis. Nat Rev Neurol. 2023;19(5):289\u2013304. https:\/\/doi.org\/10.1038\/s41582-023-00800-7.","journal-title":"Nat Rev Neurol"},{"issue":"9","key":"931_CR40","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S1474-4422(21)00237-4","volume":"20","author":"DS Reich","year":"2021","unstructured":"Reich DS, Arnold DL, Vermersch P, Bar-Or A, Fox RJ, Matta A, et al. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2021;20(9):729\u201338. https:\/\/doi.org\/10.1016\/S1474-4422(21)00237-4.","journal-title":"Lancet Neurol"},{"issue":"11","key":"931_CR41","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S1474-4422(24)00328-4","volume":"23","author":"X Montalban","year":"2024","unstructured":"Montalban X, Vermersch P, Arnold DL, Bar-Or A, Cree BAC, Cross AH, et al. Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials. Lancet Neurol. 2024;23(11):1119\u201332. https:\/\/doi.org\/10.1016\/S1474-4422(24)00328-4.","journal-title":"Lancet Neurol"},{"key":"931_CR42","unstructured":"Oh J, Fox RJ, Arnold DL, Syed S, Vargas WS, Li Y, et al., editors. Paramagnetic rim lesions as a prognostic and predictive biomarker in Tolebrutinib Phase 3 trials for disability outcomes. ACTRIMS 2025, 27 February\u201301 March 2025; 2025; West Palm Beach."},{"issue":"1","key":"931_CR43","doi-asserted-by":"publisher","DOI":"10.1136\/bmjno-2021-000240","volume":"4","author":"V Beynon","year":"2022","unstructured":"Beynon V, George IC, Elliott C, Arnold DL, Ke J, Chen H, et al. Chronic lesion activity and disability progression in secondary progressive multiple sclerosis. BMJ Neurol Open. 2022;4(1):e000240. https:\/\/doi.org\/10.1136\/bmjno-2021-000240.","journal-title":"BMJ Neurol Open"},{"issue":"3","key":"931_CR44","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1177\/13524585221141964","volume":"29","author":"A Calvi","year":"2023","unstructured":"Calvi A, Clarke MA, Prados F, Chard D, Ciccarelli O, Alberich M, et al. Relationship between paramagnetic rim lesions and slowly expanding lesions in multiple sclerosis. Mult Scler. 2023;29(3):352\u201362. https:\/\/doi.org\/10.1177\/13524585221141964.","journal-title":"Mult Scler"},{"issue":"5","key":"931_CR45","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000208058","volume":"102","author":"DL Arnold","year":"2024","unstructured":"Arnold DL, Elliott C, Martin EC, Hyvert Y, Tomic D, Montalban X. Effect of Evobrutinib on slowly expanding lesion volume in relapsing multiple sclerosis: a post hoc analysis of a phase 2 trial. Neurology. 2024;102(5):e208058. https:\/\/doi.org\/10.1212\/WNL.0000000000208058.","journal-title":"Neurology"},{"issue":"3","key":"931_CR46","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1177\/13524585231224702","volume":"30","author":"K Nakamura","year":"2024","unstructured":"Nakamura K, Thoomukuntla B, Bena J, Cohen JA, Fox RJ, Ontaneda D. Ibudilast reduces slowly enlarging lesions in progressive multiple sclerosis. Mult Scler. 2024;30(3):369\u201380. https:\/\/doi.org\/10.1177\/13524585231224702.","journal-title":"Mult Scler"},{"key":"931_CR47","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.msard.2017.04.008","volume":"15","author":"UW Kaunzner","year":"2017","unstructured":"Kaunzner UW, Kang Y, Monohan E, Kothari PJ, Nealon N, Perumal J, et al. Reduction of PK11195 uptake observed in multiple sclerosis lesions after natalizumab initiation. Mult Scler Relat Disord. 2017;15:27\u201333. https:\/\/doi.org\/10.1016\/j.msard.2017.04.008.","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"931_CR48","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000574","volume":"6","author":"M Sucksdorff","year":"2019","unstructured":"Sucksdorff M, Tuisku J, Matilainen M, Vuorimaa A, Smith S, Keitila J, et al. Natalizumab treatment reduces microglial activation in the white matter of the MS brain. Neurol Neuroimmunol Neuroinflamm. 2019;6(4):e574. https:\/\/doi.org\/10.1212\/NXI.0000000000000574.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"10","key":"931_CR49","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.2967\/jnumed.116.183020","volume":"58","author":"M Sucksdorff","year":"2017","unstructured":"Sucksdorff M, Rissanen E, Tuisku J, Nuutinen S, Paavilainen T, Rokka J, et al. Evaluation of the effect of fingolimod treatment on microglial activation using serial PET imaging in multiple sclerosis. J Nucl Med. 2017;58(10):1646\u201351. https:\/\/doi.org\/10.2967\/jnumed.116.183020.","journal-title":"J Nucl Med"},{"issue":"6","key":"931_CR50","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1177\/13524585231162262","volume":"29","author":"C Elliott","year":"2023","unstructured":"Elliott C, Rudko DA, Arnold DL, Fetco D, Elkady AM, Araujo D, et al. Lesion-level correspondence and longitudinal properties of paramagnetic rim and slowly expanding lesions in multiple sclerosis. Mult Scler. 2023;29(6):680\u201390. https:\/\/doi.org\/10.1177\/13524585231162262.","journal-title":"Mult Scler"},{"issue":"6","key":"931_CR51","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-025-13141-w","volume":"272","author":"M Filippi","year":"2025","unstructured":"Filippi M, Preziosa P, Rocca MA. Randomized controlled trials for multiple sclerosis: integrating pathology-driven outcomes to capture therapeutic efficacy. J Neurol. 2025;272(6):385. https:\/\/doi.org\/10.1007\/s00415-025-13141-w.","journal-title":"J Neurol"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00931-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-00931-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00931-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T14:07:45Z","timestamp":1778681265000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-00931-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["931"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-00931-1","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"25 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Paolo Preziosa received speaker honoraria from Roche, Biogen, Novartis, Merck, Bristol Myers Squibb, Genzyme, Horizon, and Sanofi. Giorgio Guido has nothing to disclose. Massimo Filippi is Editor-in-Chief of the\n                      Journal of Neurology\n                      , Associate Editor of\n                      Human Brain Mapping\n                      ,\n                      Neurological Sciences\n                      , and\n                      Radiology\n                      ; received compensation for consulting services from Almirall, Biogen, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Roche, and Sanofi; speaking activities from Amgen, Bayer, Biogen, Bristol-Myers Squibb, Celgene, Chiesi Italia SpA, Eisai, Eli Lilly, Fujirebio, Genzyme, Janssen, Merck, Neopharmed Gentili, Neuraxpharm, Novartis, Novo Nordisk, Roche, Sanofi, and Takeda, participation in Advisory Boards for Alexion, Biogen, Bristol-Myers Squibb, Eli Lilly, GE Healthcare Ltd, Merck, Neuraxpharm, Novartis, Roche, Sandoz, Sanofi, and Takeda; scientific direction of educational events for Biogen, Merck, Roche, Celgene, Bristol-Myers Squibb, Lilly, Novartis, and Sanofi-Genzyme; he receives research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla. Maria A. Rocca received consulting fees from Biogen, Bristol Myers Squibb, and Roche and speaker honoraria from Alexion, Biogen, Bristol Myers Squibb, Celgene, Horizon Therapeutics Italy, Merck Serono SpA, Mitsubishi-Tanabe Pharma, Neuraxpharm, Novartis, Roche, Sandoz, and Sanofi. She receives research support from the MS Society of Canada, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla. She is Associate Editor for\n                      Multiple Sclerosis and Related Disorders\n                      and Associate Co-Editor for Europe and Africa for\n                      Multiple Sclerosis Journal\n                      . She is also an Editorial Board member of\n                      Neurology and Therapy\n                      . She was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}